Brown Advisory’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-472,473
| Closed | -$81.3M | – | 1309 |
|
|
2021
Q3 | $81.3M | Buy |
472,473
+9,370
| +2% | +$1.23M | 0.12% | 144 |
|
|
2021
Q2 | $58.1M | Buy |
463,103
+22,683
| +5% | +$2.86M | 0.09% | 175 |
|
|
2021
Q1 | $59.7M | Buy |
440,420
+12,889
| +3% | +$1.66M | 0.1% | 159 |
|
|
2020
Q4 | $54.7M | Buy |
427,531
+6,819
| +2% | +$800K | 0.1% | 156 |
|
|
2020
Q3 | $47.3M | Buy |
420,712
+5,228
| +1% | +$520K | 0.1% | 146 |
|
|
2020
Q2 | $39.6M | Buy |
415,484
+20,443
| +5% | +$1.97M | 0.09% | 153 |
|
|
2020
Q1 | $35.5M | Buy |
395,041
+3,923
| +1% | +$305K | 0.11% | 147 |
|
|
2019
Q4 | $20.7M | Buy |
391,118
+11,951
| +3% | +$545K | 0.05% | 246 |
|
|
2019
Q3 | $15M | Buy |
379,167
+13,323
| +4% | +$578K | 0.04% | 266 |
|
|
2019
Q2 | $15M | Buy |
365,844
+2,003
| +0.6% | +$82.9K | 0.04% | 274 |
|
|
2019
Q1 | $16.9M | Buy |
363,841
+40,483
| +13% | +$1.78M | 0.05% | 277 |
|
|
2018
Q4 | $14.1M | Sell |
323,358
-206,995
| -39% | -$10.3M | 0.05% | 279 |
|
|
2018
Q3 | $30.4M | Buy |
530,353
+18,147
| +4% | +$892K | 0.09% | 205 |
|
|
2018
Q2 | $24.9M | Buy |
512,206
+7,529
| +1% | +$274K | 0.08% | 219 |
|
|
2018
Q1 | $19.7M | Buy |
504,677
+28,806
| +6% | +$1.22M | 0.06% | 233 |
|
|
2017
Q4 | $20.2M | Buy |
475,871
+15,829
| +3% | +$594K | 0.06% | 235 |
|
|
2017
Q3 | $17.2M | Buy |
460,042
+25,118
| +6% | +$872K | 0.06% | 242 |
|
|
2017
Q2 | $13.2M | Buy |
434,924
+6,000
| +1% | +$174K | 0.04% | 275 |
|
|
2017
Q1 | $11.4M | Buy |
428,924
+74,687
| +21% | +$1.97M | 0.04% | 272 |
|
|
2016
Q4 | $9.04M | Buy |
354,237
+30,465
| +9% | +$965K | 0.03% | 299 |
|
|
2016
Q3 | $11.7M | Buy |
323,772
+26,506
| +9% | +$878K | 0.04% | 268 |
|
|
2016
Q2 | $10.1M | Buy |
297,266
+13,078
| +5% | +$425K | 0.04% | 280 |
|
|
2016
Q1 | $7.5M | Buy |
284,188
+835
| +0.3% | +$24.3K | 0.03% | 306 |
|
|
2015
Q4 | $13.8M | Buy |
283,353
+16,370
| +6% | +$589K | 0.05% | 226 |
|
|
2015
Q3 | $6.65M | Buy |
266,983
+17,802
| +7% | +$535K | 0.02% | 321 |
|
|
2015
Q2 | $7.88M | Sell |
249,181
-18,023
| -7% | -$582K | 0.03% | 298 |
|
|
2015
Q1 | $10.2M | Buy |
267,204
+105,264
| +65% | +$4.19M | 0.03% | 275 |
|
|
2014
Q4 | $6.31M | Buy |
161,940
+152,616
| +1,637% | +$5.32M | 0.02% | 318 |
|
|
2014
Q3 | $282K | Buy |
+9,324
| New | +$263K | ﹤0.01% | 817 |
|
Brown Advisory's XLRN Position: Q4 2021 in Review
Brown Advisory sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 472,473 shares — an estimated $81.3M sold.
Brown Advisory first reported a position in XLRN in Q3 2014 and held it in 29 quarters. The position peaked at $81.3M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Brown Advisory reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Brown Advisory sold 472,473 Acceleron Pharma shares in Q4 2021, an estimated $81.3M.
- Brown Advisory first reported a position in Acceleron Pharma in Q3 2014 and held it in 29 quarters.
- Brown Advisory's Acceleron Pharma position peaked at $81.3M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Brown Advisory's 13F filing for Q4 2021, filed 27 Jan 2022.